←
Adam Durbin1,076 posts
Adam Durbin avatar

Adam Durbin

@ADurbinLab

Clinician-scientist Pediatric Oncologist focusing on chemical epigenetics & transcriptional circuitries. Better treatments, less toxicity. @stjuderesearch

◷ Joined April 2020▧ 57 Photos and videos
St. Jude Research avatar
⟳ Adam Durbin retweeted
St. Jude Research@StJudeResearch·Oct 26

Join Adam Shlien, PhD, @SickKidsNews, in The Science of Childhood Cancer virtual lecture series Thursday. He will discuss molecular signatures that may improve childhood cancer diagnosis and inform treatment decisions.​ Sign up now: bit.ly/4hkFOHz

Post attachment
Adam Durbin avatar
Adam Durbin@ADurbinLab·Oct 24

Amazing new mechanistic insight bridging dna repair to Epigenetics! @ongnghiem and @LabHalic!

St. Jude scientists identified a direct role for PARP1 in chromatin remodeling, revealing for the first time how the protein partially disassembles nucleosomes to make damaged DNA accessible for repair. The findings could lead to more targeted PARP1 inhibitors and potentially reduce treatment toxicity. bit.ly/4zRmFDb

hai dao avatar
⟳ Adam Durbin retweeted
hai dao@ongnghiem·Oct 23

Excited to share that our work is now published in Molecular Cell! We provide the first direct evidence for a role of hexasomes in DNA repair! Wonderful collaboration with @LabHalic, the Shelat labs, and St. Jude Imaging. cell.com/molecular-cell/full…

St. Jude Research avatar
⟳ Adam Durbin retweeted
St. Jude Research@StJudeResearch·Oct 20

Researchers identified a potential therapeutic vulnerability in a subset of osteosarcoma. In preclinical models, combining EP300 degradation with AKT inhibition slowed tumor growth and prolonged survival. The findings suggest a potential path toward more personalized treatment. bit.ly/3U3DwDt

Adam Durbin avatar
Adam Durbin@ADurbinLab·Oct 21

This work sets the stage for future work testing more drug-like EP300 degraders with AKT inhibitors in osteosarcoma and indeed, across many, many other types of cancer.

Adam Durbin avatar
Adam Durbin@ADurbinLab·Oct 21

So, in the end, we identified a group of genetically-defined osteosarcomas that are sensitive to EP300 degraders, and identified a fundamental mechanism by which degrader efficacy is affected: the control of protein synthesis. By combining these agents, we get profound synergy.

Post attachment
Adam Durbin avatar
Adam Durbin@ADurbinLab·Oct 21

Using the Cancer Cell Line Encyclopedia, we hypothesized and then showed that cells with elevated transcriptional signatures of protein synthesis are more sensitive to the combination.

Adam Durbin avatar
Adam Durbin@ADurbinLab·Oct 21

But is it restricted to osteosarcoma? To test this, we combined AKT inhibitors and JQAD1 across ~800 cancer cell lines, and demonstrated that…no! This combination works really well across lots of kinds of cancer - so how do you find which ones to combine these compounds in?

Post attachment
Adam Durbin avatar
Adam Durbin@ADurbinLab·Oct 21

This makes it hard for osteosarcoma cells to fight off the effects of JQAD1 by making new EP300. So JQAD1 causes these AKT-dysregulated osteosarcoma cells to slow down…how to make it better? Well, what about combining with AKT inhibitors? We did this and it works!

Post attachment
Adam Durbin avatar
Adam Durbin@ADurbinLab·Oct 21

We found that OSs with mutations that hyperactivate the AKT pathway are sensitive to JQAD1. Activating AKT confers sensitivity to resistant cell lines…but how? We show that AKT activity slows down protein synthesis in osteosarcoma (the opposite of what we usually think!)

Post attachment
Adam Durbin avatar
Adam Durbin@ADurbinLab·Oct 21

This map showed several cancers with selective reliance on EP300, including, sticking out like a sore thumb, osteosarcoma. Osteosarcoma (OS) is an often lethal tumor with limited clinical progress in decades.

Post attachment
Adam Durbin avatar
Adam Durbin@ADurbinLab·Oct 21

But are there other cancers sensitive to JQAD1? How do we find them? Here we used a combined functional genomics and chemical biology approach to identify cancer lineages sensitive to JQAD1 and loss of EP300.

Adam Durbin avatar
Adam Durbin@ADurbinLab·Oct 21

This was the case in the high-risk pediatric tumor neuroblastoma and was the rationale for us to develop JQAD1 - a PROTAC that targets EP300 and spares CBP (doi.org/10.1158/2159-8290.CD…). JQAD1 is well tolerated in animals due to retained CBP, but is very toxic to neuroblastoma.

Adam Durbin avatar
Adam Durbin@ADurbinLab·Oct 21

This was a major effort between the @Adurbinlab @TheAbraLab @JunQiLab and the Ory labs. We pick up on a long-term interest of our labs: the attractive target, EP300. EP300 is a great cancer target because while many tumor cells require it, they often may not need its paralog CBP

Post attachment